Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease

Neurochem Int. 2020 Dec:141:104881. doi: 10.1016/j.neuint.2020.104881. Epub 2020 Oct 15.

Abstract

Alzheimer's disease (AD) constitutes the leading cause of dementia worldwide. It is associated to amyloid-β (Aβ) aggregation and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Evidence suggests that the canonical Wnt pathway is deregulated in AD. Pathway activity is mediated by β-catenin stabilization in the cytosol, and subsequent translocation to the nucleus to regulate the expression of several genes implicated in brain homeostasis and functioning. It was recently proposed that Dickkopf-related protein-1 (DKK1), an endogenous antagonist of the pathway, might be implicated in AD pathogenesis. Here, we hypothesized that canonical Wnt pathway deactivation associated to DKK1 induction contributes to late-onset AD pathogenesis, and thus DKK1 neutralization could attenuate AD pathology. For this purpose, human post-mortem AD brain samples were used to assess pathway activity, and aged APPswe/PS1 mice were used to investigate DKK1 in late-onset AD-like pathology and therapy. Our findings indicate that β-catenin levels progressively decrease in the brain of AD patients, correlating with the duration of symptoms. Next, we found that Aβ pathology in APPswe/PS1 mediates DKK1 induction in the brain. Pharmacological neutralization of DKK1's biological activity in APPswe/PS1 mice restores pathway activity by stabilizing β-catenin, attenuates Aβ pathology, and ameliorates the memory of mice. Attenuation of AD-like pathology upon DKK1 inhibition is accompanied by a reduced protein expression of beta-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE1). Moreover, DKK1 inhibition enhances vascular density, promotes blood-brain barrier (BBB) integrity by increasing claudin 5, glucose transporter-1 (GLUT1), and ATP-binding cassette sub-family B member-1 (ABCB1) protein expression, as well as ameliorates synaptic plasticity by increasing brain-derived neurotrophic factor (BDNF), and postsynaptic density protein-95 (PSD-95) protein expression. DKK1 conditional induction reduces claudin 5, abcb1, and psd-95 mRNA expression, validating its inhibition effects. Our results indicate that neutralization of DKK1's biological activity attenuates AD-like pathology by restoring canonical Wnt pathway activity.

Keywords: Alzheimer's disease; Amyloid-beta; Blood-brain barrier; Canonical Wnt pathway; Memory; Synaptic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / pathology*
  • Alzheimer Disease / psychology
  • Amyloid Precursor Protein Secretases / genetics
  • Amyloid beta-Peptides* / genetics
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • Aspartic Acid Endopeptidases / genetics
  • Behavior, Animal
  • Blood-Brain Barrier / pathology
  • Brain / pathology
  • Claudin-5 / genetics
  • Disks Large Homolog 4 Protein / genetics
  • Humans
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Mice
  • Peptide Fragments / genetics
  • Wnt Signaling Pathway / drug effects
  • beta Catenin / metabolism

Substances

  • APP protein, mouse
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Claudin-5
  • Cldn5 protein, mouse
  • DKK1 protein, human
  • Disks Large Homolog 4 Protein
  • Dlg4 protein, mouse
  • Intercellular Signaling Peptides and Proteins
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • beta Catenin
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases
  • Bace1 protein, mouse